Search
Now showing items 381-390 of 467
Milestones in dosimetry for nuclear medicine therapy.
(Oxford University Press (OUP), 2022-07-01)
Nuclear Medicine therapy has reached a critical juncture with an unprecedented number of patients being treated and an extensive list of new radiopharmaceuticals under development. Since the early applications of these ...
Personalized (N-of-1) Trials for Patient-Centered Treatments of Multimorbidity.
(MIT Press, 2022-09-08)
Treatment of patients who suffer from concurrent health conditions is not well served by (1) evidence-based clinical guidelines that mainly specify treatment of single conditions and (2) conventional randomized controlled ...
Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer.
(AMER ASSOC CANCER RESEARCH, 2022-08-15)
PURPOSE: Therapies targeting the androgen receptor (AR) have improved the outcome for patients with castration-sensitive prostate cancer (CSPC). Expression of the constitutively active AR splice variant-7 (AR-V7) has shown ...
Characterisation of a Novel Cell Line (ICR-SS-1) Established from a Patient-Derived Xenograft of Synovial Sarcoma.
(MDPI, 2022-08-04)
Synovial sarcoma is a rare translocation-driven cancer with poor survival outcomes, particularly in the advanced setting. Previous synovial sarcoma preclinical studies have relied on a small panel of cell lines which suffer ...
Liquid biopsy for children with central nervous system tumours: Clinical integration and technical considerations.
(FRONTIERS MEDIA SA, 2022-11-16)
Circulating cell-free DNA (cfDNA) analysis has the potential to revolutionise the care of patients with cancer and is already moving towards standard of care in some adult malignancies. Evidence for the utility of cfDNA ...
The 5-Hydroxymethylcytosine Landscape of Prostate Cancer.
(AMER ASSOC CANCER RESEARCH, 2022-11-02)
UNLABELLED: Analysis of DNA methylation is a valuable tool to understand disease progression and is increasingly being used to create diagnostic and prognostic clinical biomarkers. While conversion of cytosine to ...
Intrinsic Molecular Subtypes of Metastatic Castration-Resistant Prostate Cancer.
(AMER ASSOC CANCER RESEARCH, 2022-12-15)
PURPOSE: Although numerous biology-driven subtypes have been described previously in metastatic castration-resistant prostate cancer (mCRPC), unsupervised molecular subtyping based on gene expression has been less studied, ...
Reclassifying tumour cell cycle activity in terms of its tissue of origin.
(NATURE PORTFOLIO, 2022-08-20)
Genomic alterations resulting in loss of control over the cell cycle is a fundamental hallmark of human malignancies. Whilst pan-cancer studies have broadly assessed tumour genomics and their impact on oncogenic pathways, ...
Developing and testing a robotic MRI/CT fusion biopsy technique using a purpose-built interventional phantom.
(SPRINGER WIEN, 2022-11-22)
BACKGROUND: Magnetic resonance imaging (MRI) can be used to target tumour components in biopsy procedures, while the ability to precisely correlate histology and MRI signal is crucial for imaging biomarker validation. ...
Immunotherapy of sarcomas with modified T cells.
(LIPPINCOTT WILLIAMS & WILKINS, 2022-07-01)
PURPOSE OF REVIEW: To summarize the development of modified T-cell therapies in sarcomas and discuss relevant published and ongoing clinical trials to date. RECENT FINDINGS: Numerous clinical trials are underway evaluating ...